This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-29. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
=== Filler injections === Filler injections of collagen can be used to raise atrophic scars to the level of surrounding skin. Risks vary based upon the filler used, and can include further disfigurement and allergic reaction.
=== Tracking === The headset and controllers both use lighthouse tracking systems, while retaining full compatibility with all previous HTC Vive base stations, using SteamVR. The Valve Index utilizes Valve's Lighthouse 2.0 tracking system, which involves external base stations to establish a 3D tracking environment. These base stations are small, rectangular units placed around the room that emit non-visible infrared light and laser patterns. The headset and controllers, equipped with sensors, detect these signals to determine their position and orientation. Each base station includes two rapidly spinning laser emitters that project a sweeping pattern of lasers across the room. Unlike the Lighthouse 1.0, which used an infrared Sync Blinker for synchronization, Lighthouse 2.0 employs a more refined synchronization mechanism integrated into the laser system itself. The sensors on the headset and controllers detect the laser beams to determine their exact positions relative to the base stations. Typically, two base stations are used to ensure comprehensive coverage and minimize occlusion, though additional base stations can be added to extend the tracking range. Although the Valve Index uses external base stations, the tracking system is considered inside-out because the tracking sensors are mounted on the tracked devices themselves—the headset and controllers. These sensors process the tracking information internally, which differentiates it from traditional outside-in systems that use fixed cameras or sensors to monitor the tracked objects from outside.
Ibogamine is an anti-convulsant, anti-addictive, CNS stimulant alkaloid found in Tabernanthe iboga and Crepe Jasmine (Tabernaemontana divaricata). Basic research related to how addiction affects the brain has used this chemical.
=== Awards === In April 2025, Peña was awarded the AJC Gesher Award from the American Jewish Committee in recognition of his support of Israel. In May 2026, he received an honorary degree from the National Taiwan University of Science and Technology.
=== Surgery === The surgery to repair the anterior vaginal wall may be combined with other procedures that will repair the other points of pelvic organ support such as anterior-posterior repair and anterior colporrhaphy. Treatment of cystocele often accompanies the more invasive hysterectomy. Since the failure rate in cystocele repair remains high, additional surgery may be needed. Women who have surgery to repair a cystocele have a 17% chance of needing another operation within the next ten years. The surgical treatment of cystocele will depend on the cause of the defect and whether it occurs at the top (apex), middle, or lower part of the anterior vaginal wall. The type of surgery will also depend on the type of damage that exists between supporting structures and the vaginal wall. One of the most common surgical repairs is colporrhaphy. This surgical procedure consists of making a longitudinal folding of the vaginal tissue, suturing it into place and creating a stronger point of resistance to the intruding bladder wall. Surgical mesh is sometimes used to strengthen the anterior vaginal wall. It has a 10–50% failure rate. In some cases a surgeon may choose to use surgical mesh to strengthen the repair. During surgery, the repair of the vaginal wall consists of folding over and then suturing the existing tissue between the vagina and bladder to strengthen it. This tightens the layers of tissue to promote the replacement of the pelvic organs into their normal place. The surgery also provides more support for the bladder.
Sources: en.wikipedia.org
Shear-thickening (dilatant) liquids, whose viscosity increases with the rate of shear strain. Shear-thinning liquids, whose viscosity decreases with the rate of shear strain. Thixotropic liquids, that become less viscous over time when shaken, agitated, or otherwise stressed. Rheopectic liquids, that become more viscous over time when shaken, agitated, or otherwise stressed. Bingham plastics that behave as a solid at low stresses but flow as a viscous fluid at high stresses. Trouton's ratio is the ratio of extensional viscosity to shear viscosity. For a Newtonian fluid, the Trouton ratio is 3. Shear-thinning liquids are very commonly, but misleadingly, described as thixotropic. Viscosity may also depend on the fluid's physical state (temperature and pressure) and other, external, factors. For gases and other compressible fluids, it depends on temperature and varies very slowly with pressure. The viscosity of some fluids may depend on other factors. A magnetorheological fluid, for example, becomes thicker when subjected to a magnetic field, possibly to the point of behaving like a solid.
== See also == Homologous series, for homo- prefix Cysteine metabolism Taurine, sulfur-containing acidic compound with amino group, but not classified as amino acid. The compound is a sulfonic acid, and amino acid definition only allows carboxylic acids. List of MeSH codes (D02) § MeSH D02.886.030 – amino acids, sulfur List of MeSH codes (D12.125) § MeSH D12.125.166 – amino acids, sulfur
2026 United States federal budget – $6.8 trillion (submitted 2025 by President Trump) 2025 United States federal budget – $7 trillion (submitted 2024 by President Biden) 2024 United States federal budget – $6.8 trillion (submitted 2023 by President Biden) 2023 United States federal budget – $6.1 trillion (submitted 2022 by President Biden) 2022 United States federal budget – $6.3 trillion (submitted 2021 by President Biden) 2021 United States federal budget – $6.8 trillion (submitted 2020 by President Trump) 2020 United States federal budget – $6.5 trillion (submitted 2019 by President Trump) 2019 United States federal budget – $4.4 trillion (submitted 2018 by President Trump) 2018 United States federal budget – $4.1 trillion (submitted 2017 by President Trump) 2017 United States federal budget – $4.2 trillion (submitted 2016 by President Obama) 2016 United States federal budget – $4 trillion (submitted 2015 by President Obama) 2015 United States federal budget – $3.9 trillion (submitted 2014 by President Obama) 2014 United States federal budget – $3.5 trillion (submitted 2013 by President Obama) 2013 United States federal budget – $3.8 trillion (submitted 2012 by President Obama) 2012 United States federal budget – $3.7 trillion (submitted 2011 by President Obama) 2011 United States federal budget – $3.8 trillion (submitted 2010 by President Obama) 2010 United States federal budget – $3.6 trillion (submitted 2009 by President Obama) 2009 United States federal budget – $3.5 trillion (submitted 2008 by President Bush) 2008 United States federal budget – $2.9 trillion (submitted 2007 by President Bush) 2007 United States federal budget – $2.8 trillion (submitted 2006 by President Bush) 2006 United States federal budget – $2.7 trillion (submitted 2005 by President Bush) 2005 United States federal budget – $2.4 trillion (submitted 2004 by President Bush) 2004 United States federal budget – $2.3 trillion (submitted 2003 by President Bush) 2003 United States federal budget – $2.2 trillion (submitted 2002 by President Bush) 2002 United States federal budget – $2 trillion (submitted 2001 by President Bush) 2001 United States federal budget – $1.9 trillion (submitted 2000 by President Clinton) 2000 United States federal budget – $1.8 trillion (submitted 1999 by President Clinton) 1999 United States federal budget – $1.7 trillion (submitted 1998 by President Clinton) 1998 United States federal budget – $1.7 trillion (submitted 1997 by President Clinton) 1997 United States federal budget – $1.6 trillion (submitted 1996 by President Clinton) 1996 United States federal budget – $1.6 trillion (submitted 1995 by President Clinton) The budget year runs from October 1 to September 30 the following year and is submitted by the President to Congress prior to October for the following year. In this way the budget of 2013 is submitted before the end of September 2012. This means that the budget of 2001 was submitted by Bill Clinton and was in force during most of George W. Bush's first year in office. The budget submitted by George W. Bush in his last year in office was the budget of 2009, which was in force through most of Barack Obama's first year in office. The President's budget also contains revenue and spending projections for the current fiscal year, the coming fiscal years, as well as several future fiscal years. In recent years, the President's budget contained projections five years into the future. The Congressional Budget Office (CBO) issues a "Budget and Economic Outlook" each January and an analysis of the President's budget each March. CBO also issues an updated budget and economic outlook in August. Actual budget data for prior years is available from the Congressional Budget Office; see the "Historical Budget Data" links on the main page of "The Budget and Economic Outlook". and from the Office of Management and Budget (OMB).
The ELISA was the first screening test widely used for HIV because of its high sensitivity. In an ELISA, a person's serum is diluted 400 times and applied to a plate to which HIV antigens are attached. If antibodies to HIV are present in the serum, they may bind to these HIV antigens. The plate is then washed to remove all other components of the serum. A specially prepared "secondary antibody"—an antibody that binds to other antibodies—is then applied to the plate, followed by another wash. This secondary antibody is chemically linked in advance to an enzyme. Thus, the plate will contain enzyme in proportion to the amount of secondary antibody bound to the plate. A substrate for the enzyme is applied, and catalysis by the enzyme leads to a change in color or fluorescence. ELISA results are reported as a number; the most controversial aspect of this test is determining the "cut-off" point between a positive and a negative result. A cut-off point may be determined by comparing it with a known standard. If an ELISA test is used for drug screening at workplace, a cut-off concentration, 50 ng/ml, for example, is established, and a sample containing the standard concentration of analyte will be prepared. Unknowns that generate a stronger signal than the known sample are "positive". Those that generate weaker signal are "negative". There are ELISA tests to detect various kind of diseases, such as dengue, malaria, Chagas disease, Johne's disease, and others. ELISA tests also are extensively employed for in vitro diagnostics in medical laboratories. The other uses of ELISA include:
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.